Compass Therapeutics CSO Susan Kalled departs effective Nov 29, 2022

Compass Therapeutics, Inc.

Susan Kalled, PhD, resigned as Chief Scientific Officer on November 29, 2022.
Entitled to 12 months base salary severance paid in installments over 12 months.
Eligible for up to 12 months COBRA premium reimbursement, contingent on separation agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Susan Kalled, PhD

Chief Scientific Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2022-11-29
Filed: November 29, 2022, 6:59 PM ET

On November 29, 2022, Susan Kalled, PhD departed her position as Chief Scientific Officer of Compass Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Kalled, PhD departed as Chief Scientific Officer at Compass Therapeutics, Inc..

Action: departed
Role: Chief Scientific Officer

Exact text from the filing

On November 29, 2022, Susan Kalled, PhD departed her position as Chief Scientific Officer of Compass Therapeutics, Inc.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.